Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The effect of N-terminal acetylation and the inhibition activity of acetylated enkephalins on the aminopeptidase M-catalyzed hydrolysis of enkephalins☆

Dhammika S. Jayawardene, Chhabil Dass*

Department of Chemistry, University of Memphis, Memphis, TN 38152, USA

Received 17 December 1998; accepted 12 April 1999

Abstract

High performance liquid chromatography and high performance liquid chromatography/electrospray ionization-mass spectrometry were used to study the effect of N-terminal acetylation and the inhibition activity of acetylated enkephalins on the aminopeptidase M (EC 3.4.11.2)-catalyzed hydrolysis of methionine (Met-enk) and leucine enkephalins (Leu-enk). Acetylation imparts a significant enhancement in the proteolytic stability of these two peptides. After 30 min of the reaction, <10% of both acetylated enkephalins was hydrolyzed. In an 8-h incubation period, only a maximum of 54% Ac-Met-enk and 38% Ac-Leu-enk was hydrolyzed.

$V_{\text{max}}$ and $K_{\text{m}}$ for the degradation of Ac-Met-enk were 1.4 nmol/min/50 ng and 2.2 mM, respectively. The corresponding values for the reaction of Ac-Leu-enk were 0.5 nmol/min/50 ng and 0.9 mM. Also, the aminopeptidase M activity on Met-enk can be inhibited in the presence of Ac-Met-enk, which acts as a mixed-type inhibitor with the inhibition constant ($K_i$) of $1 \times 10^{-3}$ M. © 1999 Elsevier Science Inc. All rights reserved.

Keywords: Methionine enkephalin; Leucine enkephalin; Acetylated methionine enkephalin; Acetylated leucine enkephalin; Aminopeptidase M; Proteolytic stability; Electrospray ionization mass spectrometry

1. Introduction

Characterization of opiate receptors in the early 1970s led to the knowledge of three families of opioid peptides: endorphins, dynorphins, and enkephalins. Each family is derived from a different precursor protein [15]. Enkephalins are biochemically synthesized from preproenkephalin A and binds preferentially to δ opioid receptor [17]. Preproenkephalin A is a precursor of several opioid peptides, the most important being methionine enkephalin (Met-enk = YGGFM) and leucine enkephalin (Leu-enk = YGGFL). These two penta-peptides are found in various body tissues and are responsible for a variety of physiological activities in different tissues. They are potential candidates for analgesic drugs [18].

The pharmacological significance of these peptides, however, is diminished by the fact that they are rapidly degraded by endogenous enzymes before they can bind to their receptors [4,12,14,19,21,22,27]. The primary route of inactivation is cleavage of the Tyr-Gly bond catalyzed by the soluble membrane-bound aminopeptidases (see Fig. 1). Other enzymes involved in the inactivation of enkephalins are dipeptidylaminopeptidase, angiotensin-converting enzyme, endopeptidase-24.11, and carboxypeptidases.

To enhance the biologic activity of enkephalins as analgesics, their proteolytic stability must be improved [13,18]. Such attempts include replacement of D amino acids for L amino acids, incorporation of unusual amino acids, and N-methylation of the amide linkages. Another innovative approach is the rational design of inhibitors for enkephalin degrading enzymes. Such compounds will prolong the lifetime of endogenously released enkephalins and may be devoid of the side-effects associated with narcotic drugs. Some of the compounds studied as inhibitors for aminopeptidases are thiorphan, amastatin, bestatin and its analogs, and kelatrophan and its analogs [2,23,24]. A recent study from our research group has demonstrated that phosphorylation of the tyrosine residue of Met-enk and Leu-enk leads to increased resistance against the aminopeptidase M (EC 3.4.11.2) activity [9].
The objective of the present study is to understand the effect of the N-terminal acetylation of enkephalins on the proteolytic activity of aminopeptidases, with a view to identify any potential inhibitory properties of acetylated methionine enkephalin (Ac-Met-enk) and acetylated leucine enkephalins (Ac-Leu-enk) on aminopeptidases action. Aminopeptidases (EC 3.4.11.X) are exopeptidases that can degrade small peptides by sequential removal of free N-terminal amino acids. They are found widely distributed in tissues of many species and are believed to be evolutionarily preserved. These enzymes are found in mammalian tissues as well as in the bacterial cells. They occur both as membrane-bound or cytosolic and are mainly metallopeptidases that require Zn^{2+} or other metal ions for their catalytic action or stability. Each type of aminopeptidases has its preferred N terminus that is cleaved more rapidly than the other N terminus. One way of classifying aminopeptidases is to categorize them according to their substrate specificity [26]. In our study, we used porcine kidney aminopeptidase M (EC 3.4.11.2), mainly because it plays a prominent role in degradation of enkephalins and it has been used for similar studies previously [6]. Benter et al. have shown that, in cerebrospinal fluid (CSF), this enzyme plays a significant role in the degradation of low molecular weight enkephalins [3]. Based on the substrate and inhibition profiles of the CSF aminopeptidase activity, they were able to rule out the involvement of several other characterized aminopeptidases. Porcine aminopeptidase M has a molecular mass of 280 kDa and is composed of 10 subunits. It has five disulfide bridges each connecting two sub units [10]. Recently, porcine aminopeptidase M also was identified as a receptor for the transmissible gastroenterovirus (corona virus TGEV), a major pathogen causing fatal diarrhea in newborn pigs [11].

In the present study, we have observed that the N-terminal acetylation imparts enhanced stability to Met-enk and Leu-enk toward the action of aminopeptidase M, and Ac-Met-enk can inhibit in vitro hydrolysis of Met-enk by binding to the enzyme and/or enzyme-substrate complex. These substrates were reacted with the enzyme at the physiological pH, and the products were identified by the techniques of high performance liquid chromatography (HPLC) and combined HPLC/electrospray ionization (ESI)-mass spectrometry (MS). With this combination, the enzymatic digest will be separated at high resolution by HPLC, and each component will be identified by highly sensitive and structure-specific ESI-MS detection [7,8].

2. Methods

2.1. Materials

Aminopeptidase M (EC 3.4.11.2), methionine enkephalin, and leucine enkephalin were purchased from Sigma (St. Louis, MO, USA), ammonium acetate was from EM Industries, and HPLC grade acetonitrile was from Fisher Scientific (Pittsburgh, PA, USA). N-acetylated enkephalins were prepared in our laboratory according to the procedure described elsewhere [6]. High-purity HPLC-grade water was prepared in-house with the Millipore Milli-Q (Bedford, MA, USA) water purification system.

2.2. Enzyme reactions

In vitro enzyme digestion was carried out at physiological temperature (37°C) and pH (7.02). All enkephalin solutions were prepared in 0.05 M Tris buffer (pH = 7.02 at 37°C). Before addition of the enzyme, the solutions of enkephalins were preincubated at least for 30 min at the above conditions. Placing the sample in boiling water for 2 min and then dipping it in dry ice terminated the enzyme reaction.

2.3. Experiment 1

2.3.1. Reaction of Ac-Met-enk and Ac-Leu-enk with aminopeptidase M

For the time course study, 50 μl of 4 mM Ac-Met-enk solution was reacted with 0.5 μg of the enzyme. Several aliquots (10 μl each) were withdrawn from the reaction mixture at different time intervals to stop the enzyme reaction. Similarly, the time-course study of the enzymatic degradation of Ac-Leu-enk was carried out by using 100 μl of 2 mM Ac-Leu-enk solution.

The kinetics of the enzyme reaction of Ac-Met-enk was studied by reacting different concentrations of Ac-Met-enk (0.2, 0.4, 0.8, 1.6, 2.4, and 4.0 mM) individually with 50 ng of the enzyme for a 1-h incubation period. For the corresponding experiments with Ac-Leu-enk, concentrations of 0.1, 0.2, 0.4, 0.8, 0.12, and 2 mM of the peptide were used.

2.4. Experiment 2

2.4.1. The inhibition activity of acetylated enkephalins on the aminopeptidase M-catalyzed hydrolysis of enkephalins

Three different solutions were prepared with the [Ac-Met-enk]/[Met-enk] ratio equal to 0.25, 0.90, and 2.0 by mixing 0.05, 0.18, and 0.40 μmol of Ac-Met-enk with three 100-μl portions of 0.20 mM Met-enk. Each of these mixtures was reacted individually with 0.5 μg of aminopeptidase M for a fixed incubation period of 10 min. A control reaction was performed in which no Ac-Met-enk was present.

Degradation of Leu-enk in the presence of the varying amounts of Ac-Leu-enk (to give [Ac-Leu-enk]/[Leu-enk] =
0.9, 2.0, and 3.0) also was studied under similar experimental conditions. The cross-over inhibition activity of acetylated enkephalins also was investigated using the same protocol. For degradation of Met-enk in the presence of Ac-Leu-enk, the [Ac-Leu-enk]/[Met-enk] ratio was adjusted to 2.0 and 3.0. For the hydrolysis reaction of Leu-enk, the [Ac-Met-enk]/[Leu-enk] ratio was equal to 2.0 and 3.0.

2.5. Experiment 3

2.5.1. The type of inhibition

To determine the type of inhibition, the kinetic parameters $V_{\text{max}}$ and $K_{m}$ were determined for the noninhibited reaction and $V_{\text{app}}$ and $K_{\text{app}}$ (app = apparent) for the inhibited reaction. For the noninhibited reaction, a portion (1.0 ml) of different concentrations of Met-enk (0.4–2.0 mM) was separately reacted with 50 ng of aminopeptidase M for an incubation period of 5 min. The experiment was repeated in the presence of 0.5 mM Ac-Met-enk, and the apparent kinetic constants ($V_{\text{app}}$ and $K_{\text{app}}$) were determined. The upper concentration of Ac-Met-enk was restricted to 0.5 mM because of solubility limitations.

2.6. Chromatography

Reversed-phase HPLC separation of the reaction products and nonreacted substrates was performed by using a HP1050 quaternary pumping system (Hewlett Packard) outfitted with a photodiode array ultraviolet-visible detector and ChemStation-based data system. The separated compounds were eluted isocratically at ambient temperature with Vydac C-18 (218TP54) column (250 × 4.6 mm inner diameter with 5-μm particle size and 300-Å pore size). Separation of the products of enzymatic degradation of Ac-enkephalins and aminopeptidase M was optimized at the flow rate of 1.5 ml/min by using a mobile phase of 20% acetonitrile in 10 mM ammonium acetate solution (pH 4.2). UV detection was carried out at 225 and 280 nm. Tyr and Tyr-containing products are detected at 280 nm [25].

In Experiment 2, the products were separated at the flow rate of 1.0 ml/min and the mobile phase composition of 12% acetonitrile in 10 mM ammonium acetate solution using the same column that was used in Experiment 1. For separation of the reaction products and the reactants of the Experiment 3, the chromatographic conditions described in Experiment 2 were used. Because of enhanced sensitivity, the ultraviolet absorbance at 225 nm was used to monitor the reaction products. Quantification of the amount of the unreacted Met-enk was based on a calibration curve constructed using a series of Met-enk solutions (0.1–2.4 mM).

2.7. Mass spectrometry

The separated reaction products were identified further by their mass-to-charge (m/z) ratio by using a Micromass Platform II mass spectrometer (Micromass, Manchester, UK), operated in the ESI mode. The LC column was connected to the ESI probe by means of a flow splitter, which permitted only a fraction (200 μl/min) of the LC eluent to enter into the ESI source maintained at 180°C. Nitrogen was used both as nebulizing and drying gas at the flow rates of 15 l/h and 350 l/h, respectively. The sampling cone voltage was set to 30 V. These experimental parameters were optimized to minimize the formation of solvent clusters, which otherwise contribute significantly to the background chemical noise [28]. The MS data were acquired in the form of total ion current chromatograms by scanning the quadrupole in the positive-ion mode at a scan rate of 0.1s/scan and mass range of 145–625 Da. The instrument was controlled by a PC-based Masslynx data system.
3. Results

3.1. Reaction of Ac-Met-enk and Ac-Leu-enk with aminopeptidase M

Typical chromatograms illustrating the analysis of the reaction products of the reaction of Ac-Met-enk with aminopeptidase M are shown in Fig. 2. Similar chromatograms were obtained for the reaction of Ac-Leu-enk (not shown). The increase of the peak area of the Ac-Tyr (retention time, 2.0 min) was used as a marker of the progress of the reaction.

The progress of the hydrolysis reaction of Ac-Met-enk and Ac-Leu-enk is shown in Figs. 3 and 4, respectively. Almost 90% of both acetylated peptides remained intact after 30 min of the start of the reaction. A maximum of only 54% of Ac-Met-enk and 38% of Ac-Leu-enk were hydrolyzed at the end of 8-h incubation period. In contrast, unmodified Met-enk and Leu-enk are completely hydrolyzed by aminopeptidase M under identical experimental conditions within 1 min of the reaction (data not shown). The Hanes–Woolf plot, which is a plot of the ratio of [Met-enk]/(reaction-rate) against [Met-enk], was used to calculate the $V_{\text{max}}$ and $K_m$ values. Because of equal error distribution in both high and low concentration extremes, this plot is preferably used in obtaining precise estimates for these kinetic constants [5]. The values of the $V_{\text{max}}$ and $K_m$ for the degradation of Ac-Met-enk are found to be 1.4 nmol/min/50 ng and 2.2 mM, respectively. The corresponding values for the reaction involving Ac-Leu-enk are 0.5 nmol/min/50 ng and 0.9 mM, respectively.

3.2. The inhibition activity of acetylated enkephalins on the aminopeptidase M-catalyzed hydrolysis of enkephalins

In contrast to the control experiment, in which the Met-enk is completely hydrolyzed within the incubation period of 10 min, intact Met-enk was detected in the presence of Ac-Met-enk (see Table 1). With increase in the ratio of [Ac-Met-enk]/[Met-enk], the extent of degradation of Met-enk (as measured by the peak area of Tyr in the HPLC chromatogram) was reduced considerably. At the ratio of 2.0, only 21% of the original amount of Met-enk was hydrolyzed as compared to complete hydrolysis in the absence of Ac-Met-enk. At 280 nm, only Tyr and Met-enk and Ac-Met-enk were detected at the retention times of 4.0, 9.3, and 11.4 min, respectively. At 225 nm, a few additional peaks corresponding to FM (at 4.8 min) and GGFM (at 6.2 min) also were detected.

By using HPLC/ESI-MS analysis, reaction products were identified further by their m/z ratio. In the control experiment, ions corresponding to Tyr (m/z 182; at 4.0 min), FM (m/z 297, at 5.0 min), and GGFM (m/z 411, at 6.1 min) were detected (Fig. 5a). Met-enk (m/z 574) and YGG (m/z 296) were not detected. In the inhibited reaction mixture, molecular ions of Tyr, GGFM, Met-enk, and Ac-Met-enk (m/z 616) were detected at 4.0, 6.1, 9.3, and 11.4 min, respectively (Fig. 5b). However, Ac-Tyr (m/z 224) as well as YGG and FM were not detected.

The results of the degradation of Leu-enk in the presence of the varying amounts of Ac-Leu-enk also are included in Table 1. In this experiment, even at the [Ac-Leu-enk]/[Leu-enk] ratio of 0.25, only 100% degradation of Leu-enk was observed.

Table 1

| [Ac-Met-enk]/[Met-enk] | % Degradation | [AC-Leu-enk]/[Leu-enk] | % Degradation |
|------------------------|---------------|------------------------|---------------|
| 0.25                   | 100.00 ± 0    | 0.90                   | 100.00 ± 0    |
| 0.90                   | 43.00 ± 2     | 2.00                   | 98.00 ± 0.5   |
| 2.00                   | 21.00 ± 9     | 3.00                   | 94.00 ± 0.8   |

Fig. 3. The rate of disappearance of Ac-Met-enk (circles) and appearance of Ac-Tyr (squares). Ac-Met-enk was reacted with aminopeptidase M at 37°C and pH 7.02. % Peak area, the % peak area of Ac-Tyr or Ac-Met-enk relative to the sum of the peak areas of Ac-Tyr and Ac-Met-enk.

Fig. 4. The rate of disappearance of Ac-Leu-enk (circles) and appearance of Ac-Tyr (squares). Ac-Leu-enk was reacted with aminopeptidase M at 37°C and pH 7.02. % Peak area, the % peak area of Ac-Tyr or Ac-Met-enk relative to the sum of the peak areas of Ac-Tyr and Ac-Leu-enk.
enk] ratio of 3.0, only 6% of the original amount of Leu-enk remained intact. In the enzyme hydrolysis reactions of Leu-enk and Met-enk carried out in the presence of Ac-Met-enk and Ac-Leu-enk, respectively, both Leu-enk and Met-enk were hydrolyzed completely within the incubation period of 10 min.

3.3. The type of inhibition

The data for the noninhibited reaction and inhibited reactions are compared in Figs. 6 and 7. The Fig. 6a, which is the plot of reaction rate vs. the concentration of Met-enk, indicates that the reaction rate in the inhibited reaction is lowered. The kinetic constants for the noninhibited ($V_{\text{max}}$ and $K_m$) and the inhibited ($V_{\text{app}}$ and $K_{\text{app}}$) reactions were determined by the Hanes–Woolf Plot. The data in Table 2 clearly indicate that there was a significant decrease in $V_{\text{app}}$ and $K_{\text{app}}$ compared with $V_{\text{max}}$ and $K_m$. As described above, the Hanes–Woolf Plot gives better estimates for $V_{\text{max}}$ and $K_m$. However, in the literature, the Lineweaver–Burk plot is used most commonly for the purpose of describing the types of inhibition. Therefore, to identify the type of inhibition, the Lineweaver–Burk plots (Fig. 7) were drawn from the values of $V_{\text{max}}$, $K_m$, $V_{\text{app}}$, and $K_{\text{app}}$ obtained from the Hanes–Woolf plot.

3.4. Statistical analyses

In Tables 1 and 2, the data are presented as ± SD. The kinetic constants for the inhibited and noninhibited reactions were compared using the Hanes–Woolf and Lineweaver–Burk plots.
Comparison of the kinetic constants calculated for the noninhibited reaction and the inhibited reaction

Table 2
Comparison of the kinetic constants calculated for the noninhibited reaction and the inhibited reaction

| Kinetic constants | Noninhibited reaction | Inhibited reaction |
|-------------------|-----------------------|--------------------|
| $V_{\text{max}}$ nmol/min/50 ng | 130 ± 9 | 80 ± 5* |
| $K_m$ mM | 0.8 ± 0.1 | 0.3 ± 0.07* |

* The Met-enk and aminopeptidase M reaction.

* The Met-enk and aminopeptidase M reaction in the presence of Ac-Met-enk.

* $P < 0.01$.

Figure 7. The Lineweaver–Burk plots for the inhibited reaction (dotted line) and the noninhibited reaction (dark line). These plots were drawn based upon the $K_m$ and $V_{\text{max}}$ values obtained from the Hanes–Woolf plots in Fig. 6b. $V$ and $[S]$ are the same as in Fig. 6.

4. Discussion

In an effort to understand the role of N-terminal acetylation in enhancing the proteolytic stability of enkephalins, we have investigated the aminopeptidase M-catalyzed proteolysis of Ac-Met-enk and Ac-Leu-enk. As shown in Fig. 1, the first step of the aminopeptidase M-catalyzed hydrolysis of both these enkephalins will result in the formation of Ac-Tyr residue and the des-Ac-Tyr products, GGFM or GGFL, respectively. The predominant degradation product for both the substrates, however, is Ac-Tyr. The des-Ac-Tyr products were not detected perhaps because of the longer time interval (1 h) between two consecutive samplings. During this time interval, the initially formed GGFM (or GGFL) is hydrolyzed rapidly by sequential removal of the terminal amino acids. Therefore, the progress of the reaction was monitored based on the Ac-Tyr peak area. It is likely that other amino acids, especially Phe, generated during hydrolysis of acetylated enkephalins may coelute with Ac-Tyr. However, it was observed by us using the standard samples that Phe is not detected at 280 nm (results not shown). Under these chromatographic conditions, only Ac-Tyr, Tyr, Met-enk, and Ac-Met-enk responded at 280 nm.

According to the results obtained in the Experiment 1, a significant proteolytic stability is demonstrated for Ac-Met-enk and Ac-Leu-enk against the activity of aminopeptidase M. The enhancement of the stability is greater than what had been observed previously by us due to phosphorylation of the Tyr residue [9]. This enhancement in stability due to acetylation is somewhat predictable because N-acetylation blocked the free amino terminal, which is considered an important site for aminopeptidase action [10].

Although N-terminal acetylation of enkephalins has imparted significant proteolytic stability, some enzymatic activity is still detected during the hydrolysis of Ac-Met-enk and Ac-Leu-enk. This observation led us to believe that Ac-Met-enk and Ac-Leu-enk may play the role of inhibitors in the degradation of enkephalins by competing for the aminopeptidase M activity. To test this hypothesis, we studied the enzymatic degradation of Met-enk and Leu-enk in the presence of their corresponding acetylated analogues (Experiment 2).

When acetylated and nonacetylated Met-enk were both present in the reaction mixture, it was necessary to use different chromatographic conditions than employed in the study of degradation of acetylated enkephalins. Chromatographic separation was optimized by using 12% acetonitrile in ammonium acetate buffer as the mobile phase at a flow rate of 1.0 ml/min. Under these conditions, both Tyr and Ac-Tyr elute at nearly the same retention time (4.0 min). However, the contribution of Ac-Tyr to the peak area of Tyr is negligible because degradation of Ac-Met-enk does not occur to any appreciable extent during the short incubation period (10 min) used in these experiments. This finding was further confirmed by HPLC/ESI-MS analysis of the reaction products. No Ac-Tyr was detected in the ion chromatogram. ESI-MS analysis of the reaction products also revealed the absence of the molecular ions of YG, YGG, and GG in the ion current chromatograms, indicating that the enzyme preparations used by us does not contain other enkephalin-degrading enzymes (Fig. 1) as impurities. It has been reported earlier that commercial preparations of kidney aminopeptidase M may be contaminated with neutral metalloendopeptidase [1]. If endopeptidase activity were present, it should have produced both YG and FM. The absence of YG molecular ion in the ESI-MS ion chromatogram rules out the possible contamination of aminopeptidase M with endopeptidases.

Decrease in the amount of degradation of Met-enk from 100% in the control experiment to 21% in the presence of Ac-Met-enk clearly indicates that Ac-Met-enk inhibits the aminopeptidase M-catalyzed hydrolysis of Met-enk. The absence of FM in this reaction mixture further supports this
Inhibition of the aminopeptidase M activity also would affect the hydrolysis of subsequent N-terminal residues.

It was observed that Ac-Leu-enk is not as strong an inhibitor of the aminopeptidase M activity on the hydrolysis of Leu-enk as Ac-Met-enk is on the corresponding reaction of Met-enk. This observation is consistent with the fact that Ac-Leu-enk has lower affinity for aminopeptidase M compared to Ac-Met-enk (compare the \( V_{\text{max}} \) values shown above). Also, no inhibition activity was found when Ac-Met-enk and Ac-Leu-enk were interchanged as inhibitors for the aminopeptidase M activity on Leu-enk and Met-enk, respectively. This intriguing observation can also be explained partially on the basis of relative affinities of Met-enk and Leu-enk for aminopeptidase M. Benter et al. [3] have reported that \( V_{\text{max}} \) for the hydrolysis of the Tyr-Gly bond in human CSF is higher for Leu-enk (2.0 nmol/min/ml) than for Met-enk (400 pmol/min/ml).

The knowledge of the type of inhibition also may provide some explanation why Ac-Met-enk inhibits the hydrolysis of Met-enk and not Leu-enk. Inhibitors are classified as competitive, noncompetitive, uncompetitive, and mixed type [5,16,20]. Each type exhibits a characteristic deviation from the typical Lineweaver–Burk plot of the uninhibited reaction. Competitive inhibitors inhibit the enzyme action by binding to the same active site as the substrate. They increase the \( K_m \) but do not affect \( V_{\text{max}} \). With noncompetitive type inhibitors, \( V_{\text{max}} \) is decreased but \( K_m \) remains unaffected. The noncompetitive inhibitors and the substrate bind to the enzyme reversibly, randomly, and independently at different sites. A pure uncompetitive inhibitor binds reversibly to the enzyme–substrate complex yielding an inactive enzyme–substrate–inhibitor complex. Its behavior is characterized by the decrease in both \( K_m \) and \( V_{\text{max}} \). The corresponding Lineweaver–Burk plot of the uncompetitive inhibition runs parallel to the plot of the noninhibited reaction. Unlike the competitive inhibition, the degree of inhibition increases with the increase in the substrate concentration in the uncompetitive inhibition because the enzyme is inactivated by the formation of an enzyme–substrate–inhibitor complex. If more than one of the above mechanisms are operative at the same time, the resulting inhibition is called mixed type, which is characterized by change in both \( K_m \) and \( V_{\text{max}} \).

Experiment 3 was performed to determine the type of inhibition and the corresponding inhibition constant. The data presented in Figs. 6 and 7 and Table 2 confirm that Ac-Met-enk can indeed inhibit aminopeptidase M-catalyzed hydrolysis of Met-enk. The presence of the uncompetitive inhibitor component is indicated clearly by the decrease in both \( K_m \) (from 0.8 to 0.3 mM) and \( V_{\text{max}} \) (from 130 to 80 nmol/min/50 ng). The observation that the inhibition activity is prominent at higher substrate concentrations further supports this evidence. The Lineweaver–Burk plot (Fig. 7), however, does not obey the typical pattern (the plots of both inhibited and uninhibited reactions should be parallel) of a pure noncompetitive inhibition. Therefore, the possibility of more than one mechanism exists. The deviation observed in Fig. 7 has been identified previously as due to a mixed type of inhibition [20], in which the inhibitor binds to the enzyme as well as to the enzyme–substrate complex. The inhibitor forms a dead-end complex by binding to the enzyme and reduces the total amount of enzyme molecules. It is likely that initial enzyme–Met-enk complex leads to favorable conformation in aminopeptidase M for binding to Ac-Met-enk. Because Ac-Met-enk does not behave like competitive inhibitors, it is unable to inhibit the aminopeptidase M-catalyzed hydrolysis of Leu-enk.

As explained in the experimental section, because of solubility constraints, highest [Ac-Met-enk] was limited to 0.5 mM. Therefore, 0.5 mM was considered as the limiting inhibitor concentration in calculating the inhibitor constant \( K_i \) [20]. The \( K_i \) for this system was found to be \( 1.0 \times 10^{-3} \) M \((\pm 0.7 \times 10^{-4} \) M\). The threshold concentration of the substrate Met-enk above which inhibition is prominent was found to be \(-0.5 \) mM.

In conclusion, this study has confirmed that N-acetylation of enkephalins could enhance their stability against aminopeptidase M. Also, this study has revealed that Ac-Met-enk behaves as a mixed-type inhibitor of the aminopeptidase M action on Met-enk.

References

[1] Almenoff J, Orlowski M. Membrane-bound kidney neutral metalloendopeptidase: interaction with synthetic substrates, natural substrates, natural peptides and inhibitors. Biochemistry 1986;22: 590–9.
[2] Beamount A, Fournie–Zalaski M, Rocques BP. Neutral endopeptidase-24.11: structure, and design and clinical use of inhibitors. In: Hooper NM, editor. Zinc metalloproteases in health and disease. London: Taylor & Francis, 1996. pp. 105–29.
[3] Benter IF, Hirsh EM, Tuchman AJ, Ward PE. N-terminal degradation of low molecular weight opioid peptides in human cerebrospinal fluid. Biochem Pharmacol 1990;40:465–72.
[4] Boarder MR, Mc Ardle W. Breakdown of small enkephalin derivatives and adrenalin peptide E by human plasma. Biochem Pharmacol 1986;35:1043–7.
[5] Cornish–Bowden A. Fundamentals of enzyme kinetics. London: Portland Press, 1995.
[6] Dass C, The role of a liquid matrix in controlling FAB-induced fragmentation. J Mass Spectrom 1996;31:77–82.
[7] Dass C. HPLC-electrospray ionization mass spectrometry. In: Settle F, editor. Handbook of instrumental techniques for analytical chemistry. Upper Saddle River, NJ: Prentice Hall, 1997. pp. 647–664.
[8] Dass C. Recent development and applications of HPLC-electrospray ionization mass spectrometry. Curr Org Chem 1999;3:193–209.
[9] Dass C, Mahalakshmi P. Phosphorylation of enkephalins enhances their proteolytic stability. Life Sci 1996;58:1039–45.
[10] Delange RJ, Smith EL. Leucine aminopeptidases and other N-terminal exopeptidases. In: Boyer PD, editor. The enzymes, vol. 3. New York: Academic Press, 1971. pp. 81–105.
[11] Delmas B, Gelfi J, L’Haridon R, Vogel LK, Sjoström H, Norren O, Laude H. Aminopeptidase N is a major receptor for the enteropathogenic coronavirus TGEV. Nature (London) 1992;357:417–20.
[12] Dupont A, Cusan L, Garon M, Alvaro–Urbina G, Labrie F. Extremely rapid degradation of [3H]-methionine-enkephalin by various rat tissues in vivo and in vitro. Life Sci 1977;21:907–14.

[13] Frederickson RCA. Progress in the use of enkephalin analogs. In: Rapaka RS, Hawks RL, editors. Opioid peptides, molecular pharmacology, biosynthesis, and analysis NIDA Research Monograph 70. Rockville, MD: NIDA Research Monograph Series, 1986. pp. 367–84.

[14] Hambrock JM, Morgan BA, Rance MJ. Smith CFC. Deactivation of enkephalins by rat and human plasma and rat-brain homogenates. Nature 1976;262:782–3.

[15] Hollt V. Multiple endogenous opioid peptides. Trends Neurosci 1983;6:24–6.

[16] Palmer T. Understanding enzymes. West Sussex: Ellis Limited, 1985.

[17] Peterson SJ, Robson LE, Wkosterlitz H. Opioid receptors. In: Udenfriend S, Meienhofer J, editors. The peptides, vol. 6. New York: Academic Press, 1984. pp. 147–89.

[18] Rapaka RS. Frontiers of research in the medicinal chemistry and molecular pharmacology of opioid peptides. In: Rapaka RS, Barnett G, Hawks RL, editors. Opioid peptides. Medicinal Chemistry NIDA Research Monograph 69. Rockville, MD: NIDA Research Monograph Series, 1986. pp. 3–20.

[19] Schulteis G, Weinberger SB, Martinez JL Jr. Plasma uptake and in vivo metabolism of [Leu]-Enkephalin following its intraperitoneal (i.p.) administration to rats. Peptides 1989;10:913–9.

[20] Segel IH. Enzyme kinetics. New York: John Wiley & Sons, 1975.

[21] Shibanoki S, Weinberger SB, Beniston D, Nadelman KA, Schulteis G, Bennett EL, Rosenzweig MR, Ishikawa K, Martinez JL Jr. Hydrolysis of [Leu]-enkephalin by chick plasma in vitro. J Pharmacol Exp Ther 1991;256:650–5.

[22] Shibanoki S, Weinberger SB, Ishikawa K, Martinez JL Jr. Further characterization of the in vitro hydrolysis of [Leu]-enkephalin and [Met]-enkephalin in rat plasma-HPLC-ECD measurement of substrate and metabolite concentrations. Regul Pep 1991;32:267–8.

[23] Shimamura M, Hazato T, Hachisu M, Katayama T. Inhibition of a membrane bound enkephalins degrading aminopeptidase by bestatin analogs. J Neurochem 1984;43:888–90.

[24] Thorsett ED, Wyvatt MJ. Inhibition of zinc peptidases that hydrolyze neuropeptides. In: Turner AJ, editor. Neuropeptides and their peptidases. Chichester: Ellis Horwood, 1987. pp. 229–84.

[25] Turck CW. Identification of phosphotyrosine residues in peptides by HPLC on-line derivative spectroscopy. Peptide Res 1992;5:155–60.

[26] Wang J, Cooper MD. Aminopeptidases structure and biological function. In: Hooper NM, editor. Zinc metalloproteases in health and disease. London: Taylor & Francis, 1996. pp. 131–51.

[27] Weinberger SB, Martinez JL Jr. Characterization of hydrolysis of [Leu]-enkephalin and D-Ala²-[L-Leu]-enkephalin in rat plasma. J Pharmacol Exp Ther 1988;247:129–35.

[28] Zhu X, Dass C. Analysis of phosphoenkephalins by combined HPLC and electrospray ionization mass spectrometry. J Liq Chrom Rel Technol 1999;22:1635–47.